Marilyn Glassberg Csete

Marilyn Glassberg Csete, MD

Pulmonary Disease, Internal Medicine

Provider Groups

  • Loyola Medicine Physician

  • Loyola Physician Partners

Primary Contact

888-584-7888
Please call us to discuss your appointment options
Provider Groups
  • Loyola Medicine Physician

  • Loyola Physician Partners

Primary Contact
888-584-7888

Services & Specialties

Areas of Specialization

  • Internal Medicine
  • Pulmonary Disease

Locations & Contact

Primary Location

Loyola University Medical Center

2160 S First Ave
Maywood, IL 60153

View hours
Sunday
Open 24 hours
Monday
Open 24 hours
Tuesday
Open 24 hours
Wednesday
Open 24 hours
Thursday
Open 24 hours
Friday
Open 24 hours
Saturday
Open 24 hours
Loyola University Medical Center

About

Academic Title

Professor

Ages Seen

Adults - Over 65
Adults - 18 to 64

Additional Resources

Education & Certifications

Education

Education:
University of Miami Miller School of Medicine (1985)

Education:
University of Miami Miller School of Medicine (1985)

Internship:
University of Miami Hospital & Clinics (1986)

Residency:
University of Miami Hospital & Clinics (1988)

Fellowship:
University of Miami Hospital & Clinics (1991)

Fellowship:
University of Miami Hospital (1992)

Fellowship:
University of Miami Hospital & Clinics (1992)

Board Certifications

Pulmonary Disease, Pulmonary Disease, American Board of Internal Medicine Subspecialty (1994)

Provider Groups

Loyola Medicine Physician

Loyola Physician Partners

Publications

  • Ratio of miRNA-29 to miRNA-199 expression coordinates mesenchymal stem cell repair of bleomycin-induced pulmonary injury. Elliot, S. J.; Anderson-Terhune, D.; Roos, B.; Rubio, G. A.; Xia, X.; Pereira-Simon, S.; Catanuto, P.; Civettini, G.; Hagen, E. S.; Arvanitis, C.; Shahzeidi, S.; Glassberg, M. K.; Molecular therapy. Nucleic acids
  • Impact of Environmental Exposures on the Development and Progression of Fibrotic Interstitial Lung Disease. Johannson, K. A.; Adegunsoye, A.; Behr, J.; Cottin, V.; Glanville, A. R.; Glassberg, M. K.; Goobie, G. C.; Jenkins, R. G.; Kim, J. S.; Lee, C. T.; Redlich, C. A.; Richeldi, L.; Salisbury, M. L.; Tetley, T.; Corte, T. J.; American journal of respiratory and critical care medicine
  • Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. Corte, T. J.; Behr, J.; Cottin, V.; Glassberg, M. K.; Kreuter, M.; Martinez, F. J.; Ogura, T.; Suda, T.; Wijsenbeek, M.; Berkowitz, E.; Elpers, B.; Kim, S.; Watanabe, H.; Fischer, A.; Maher, T. M.; American journal of respiratory and critical care medicine
  • Inhaled Nitric Oxide in Fibrotic Lung Disease: A Randomized, Double-Blind, Placebo-controlled Trial. Nathan, S. D.; Rajicic, N.; Dudenhofer, R.; Hussain, R.; Argula, R.; Bandyopadhyay, D.; Luckhardt, T.; Muehlemann, N.; Flaherty, K. R.; Glassberg, M. K.; Lancaster, L.; Raghu, G.; Fernandes, P.; Annals of the American Thoracic Society
  • Inflammation unites diverse acute and chronic diseases. Libby, P.; Smith, R.; Rubin, E. J.; Glassberg, M. K.; Farkouh, M. E.; Rosenson, R. S.; European journal of clinical investigation
  • The Controversy Continues: Whether to Perform Plasma Exchange, and with What Dose of Steroids, in the PEXIVAS Trial. Glassberg, M. K.; Ali, A.; Gregorini, G.; American journal of respiratory and critical care medicine
  • Genetics and Genomics of Pulmonary Fibrosis: Charting the Molecular Landscape and Shaping Precision Medicine. Adegunsoye, A.; Kropski, J. A.; Behr, J.; Blackwell, T. S.; Corte, T. J.; Cottin, V.; Glanville, A. R.; Glassberg, M. K.; Griese, M.; Hunninghake, G. M.; Johannson, K. A.; Keane, M. P.; Kim, J. S.; Kolb, M.; Maher, T. M.; Oldham, J. M.; Podolanczuk, A. J.; Rosas, I. O.; Martinez, F. J.; Noth, I.; Schwartz, D. A.; American journal of respiratory and critical care medicine
  • Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the National Institutes of Health, a Patient Advocacy Organization, and a Regulatory Agency. Raghu, G.; Ghazipura, M.; Fleming, T. R.; Aronson, K. I.; Behr, J.; Brown, K. K.; Flaherty, K. R.; Kazerooni, E. A.; Maher, T. M.; Richeldi, L.; Lasky, J. A.; Swigris, J. J.; Busch, R.; Garrard, L.; Ahn, D. H.; Li, J.; Puthawala, K.; Rodal, G.; Seymour, S.; Weir, N.; Danoff, S. K.; Ettinger, N.; Goldin, J.; Glassberg, M. K.; Kawano-Dourado, L.; Khalil, N.; Lancaster, L.; Lynch, D. A.; Mageto, Y.; Noth, I.; Shore, J. E.; Wijsenbeek, M.; Brown, R.; Grogan, D.; Ivey, D.; Golinska, P.; Karimi-Shah, B.; Martinez, F. J.; American journal of respiratory and critical care medicine
  • Efficacy and Safety of Pirfenidone in Advanced Versus Non-Advanced Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Six Clinical Studies. Behr, J.; Nathan, S. D.; Costabel, U.; Albera, C.; Wuyts, W. A.; Glassberg, M. K.; Haller, H.; Alvaro, G.; Gilberg, F.; Samara, K.; Lancaster, L.; Advances in therapy
  • Urine-derived exosomes from individuals with IPF carry pro-fibrotic cargo. Elliot, S.; Catanuto, P.; Pereira-Simon, S.; Xia, X.; Shahzeidi, S.; Roberts, E.; Ludlow, J.; Hamdan, S.; Daunert, S.; Parra, J.; Stone, R.; Pastar, I.; Tomic-Canic, M.; Glassberg, M. K.; eLife